Oncolytics lung cancer drug shrinks tumors in 92 percent of patients in trial

(Reuters) – Oncolytics Biotech Inc said its cancer drug Reolysin reduced the size of tumors in 92 percent of lung cancer patients in a mid-stage trial. The company’s shares rose as much as 22 percent to $3.22 in trading before the bell. The drug was tested on patients suffering from advanced squamous cell carcinoma of the lung. It was used intravenously in combination with chemotherapy drugs carboplatin and paclitaxel. …